World Book News -- Patients with chronic myeloid leukemia who respond to initial treatment with imatinib (Gleevec)now have a normal life expectancy, researchers reported. In a study of the long-term effects of the drug, survival of patients with a complete cytogenetic remission was not significantly different from the general population, according to Carlo Gambacorti-Passerini, MD, of the University of Milano Bicocca in Monza, Italy, and colleagues.
